Medical News Updates

This week: how quickly weight returns after stopping semaglutide or tirzepatide, why a borderline normal haemoglobin may deserve a closer look, twelve month results for automated insulin delivery in type 1 diabetes, why the testosterone dose matters for heart rhythm, and what two million people can and cannot tell us about drinks and mood. In this episode. Weight regain after stopping a GLP-1, fro...

This week: a large trial finds statins cut heart attacks and strokes in healthy over seventies but do not prevent dementia or disability, a Scandinavian study of more than 280,000 people pins down who is most at risk of ketoacidosis on flozin medicines, semaglutide and tirzepatide enter the European heart failure guidelines, immune cells appear to remember obesity for years, and four medical bodie...

This week in plain English: the first wearable that tracks glucose and ketones together, the STAREE trial on statins for healthy over 70s, why missed blood pressure pills erase their benefit, the first RAS targeted drug for pancreatic cancer, and new guidelines on cardiac rehab. Source: FDA press release, 25 Aug 2026, Libre Duo 10 Day authorization: https://www.fda.gov/news-events/press-announceme...

The FDA has authorized Libre Duo, a wearable sensor designed to monitor glucose and ketones continuously for people with diabetes aged two years and older. This Medical News Update explains how the system works, why rising ketones matter, its potential role in detecting diabetic ketoacidosis risk, and the important limitations patients and caregivers should understand. Continuous monitoring suppor...

This week, a nationwide Cyclospora outbreak tied to fast food lettuce, the first pill form of a powerful cholesterol drug, new data on activity levels for people on GLP-1 medications, a possible link between hormone exposure and thyroid cancer, and an update on the Ebola outbreak in Central Africa. Plain English, no hype.

The FDA warns TRUE METRIX meters can show one E-5 code for two very different problems. Don't stop testing — but arrange a backup meter when you can. A safety alert for anyone using a TRUE METRIX blood glucose meter. The FDA has flagged a serious problem — the same "E-5" error code can mean either dangerously high glucose OR a simple test strip error. Those need opposite responses, and getting it...

The FDA posted an Omnipod correction — some Pods may under-deliver insulin. Not every Pod is affected. Check your lot numbers and keep a backup plan. If you use an Omnipod insulin pump, here's an important safety notice — explained calmly. On May 26, 2026, the FDA posted a voluntary Medical Device Correction from Insulet because certain Pods may leak insulin and deliver less than intended. This is...

Two lots of Dexcom G7 sensors were stolen before destruction and resold. Check lot numbers 1725204004 and 1725069002. Here's what to do. A safety alert for anyone using a Dexcom G7 continuous glucose monitor. On May 26, 2026, Dexcom revealed that sensors marked for destruction were stolen and resold through unauthorized channels. This is NOT a warning about every G7 sensor — it affects two specifi...

A Mass General Brigham study links fatty liver to a 69% higher relative risk of major heart events. Why your liver is talking to your heart. Fatty liver disease — now called MASLD — is everywhere. As many as 1 in 3 American adults have some degree of it, often without knowing. For years, doctors treated it as a liver problem. A new Mass General Brigham study, using cardiac CT scans of 3,637 patien...

The SURMOUNT-MAINTAIN trial answers what happens after you stop Mounjaro or Zepbound — and offers a lower-dose maintenance option that mostly held weight off. Tirzepatide — the drug you know as Mounjaro for diabetes and Zepbound for weight loss — has produced some of the biggest weight-loss numbers we have ever seen. But everyone asks the same question: what happens when you stop? A new trial call...

A German JAMA study screened 220,000+ children for early type 1 diabetes during normal pediatric visits—catching it years before symptoms appear. For most families, type 1 diabetes shows up out of nowhere — sometimes as a child rushed to the emergency room in diabetic ketoacidosis. But a huge new study from Germany, published in JAMA, suggests we can do much better. Pediatricians in Bavaria screen...

FDA Approves Wegovy Weight-Loss Pill: What to Know About Oral Semaglutide This episode explains the first FDA-approved GLP-1 weight-loss drug in pill form: a once-daily oral semaglutide tablet (Wegovy pill) approved on December 22, 2025, with a U.S. launch in early January 2026. It clarifies that Rybelsus is also oral semaglutide but is only approved for type 2 diabetes, making Wegovy the first or...

Retatrutide Phase 3 Results: Major A1C Drops and 16.8% Weight Loss in Type 2 Diabetes This Medical News Update covers late-stage trial results for retatrutide, an investigational weight-loss and diabetes drug from Eli Lilly. On March 19, 2026, Lilly announced positive topline findings from the phase 3 TRANSCEND-T2D-1 trial in adults with type 2 diabetes, showing A1C reductions of 1.7% to 2.0% depe...

Why Ozempic Doesn’t Work for Everyone: The DNA Clue This episode explains why Ozempic and similar weight-loss drugs don’t work the same for everyone, highlighting a Stanford University study published in April 2026. Researchers found that about 10% of people carry variants in a single gene affecting the enzyme PAM, which helps activate the body’s natural GLP-1 hormone—the system these medications...

New Insights on Metabolic Health: Protect Your Brain and Heart In this week's Medical News Update, we delve into recent research revealing how metabolic health impacts more than we realize. Key studies show that weight and blood pressure may contribute to dementia and heart issues, while redefining obesity could change our health landscape. We also highlight the effects of different types of fat o...

In this episode of Medical News Update, we discuss a recent study from Denmark examining the efficacy of high-dose inactivated influenza vaccines in adults aged 65 and older, particularly those with diabetes. The study reveals that high-dose vaccines lead to fewer cardiorespiratory and cardiovascular hospitalizations compared to standard-dose vaccines. While the exact benefits vary, the findings s...

In this podcast episode, we discuss What “vascular-related dementia” means and why blood flow matters Why Mendelian randomisation strengthens causal inference, and where it can mislead The size of the BMI association and what the odds ratios imply How much of the link may run through blood pressure What listeners can do now: knowing your numbers and seeking realistic support Sources mentioned The...

In this episode of Medical News Update, we explore innovative advancements in blood glucose regulation, focusing on smart insulin and dual-hormone therapy. Researchers at Indiana University School of Medicine have developed a fusion protein that combines insulin and glucagon, offering potential stability and effectiveness in managing blood sugar levels. Early animal studies show promise, but more...

In today's episode, we discuss an important alert from the WHO regarding semaglutide medicines like Ozempic, Rybelsus, and Wegovy, which are used for type 2 diabetes and weight management. A rare but serious side effect called non-arteritic anterior ischemic optic neuropathy (NAY-on), leading to sudden vision loss, has been linked to these drugs. We review what the European Medicines Agency has fo...

Can diet sodas and sugar-free foods speed up brain ageing? A new study from the ELSA-Brasil cohort, published in Neurology , finds that artificial sweeteners are linked to faster memory and cognitive decline, especially in midlife adults and those with diabetes. In this episode, we break down the study, its strengths and limitations, and what it means for everyday dietary choices.

In this week’s episode, we explore: A potential saliva test for early diabetes risk detection Childhood obesity rates rising over 250% since 2008 GLP-1 drug usage patterns and a Medicare/Medicaid pilot program A new brain-targeted hormone approach for type 1 diabetes How a modified DASH diet is helping people with type 2 diabetes All information sourced from peer-reviewed studies: UBC Okanagan sal...

Intermittent Fasting: A Breakthrough in Diabetes Management In this episode, we explore the latest research on how occasional fasting can help manage diabetes. Learn about the benefits of intermittent fasting for blood sugar control, weight loss, and inflammation reduction. Discover how fasting, combined with modest exercise, can ease medication needs for people with type 2 diabetes. Tune in for p...

Welcome to your Medical news update! Stay informed on the latest in diabetes and obesity research and prevention. In this episode, we discuss a study showing sulforaphane in broccoli sprouts can improve blood sugar levels in prediabetes, the impact of diabetes-related prejudice, next-gen weight-loss drugs, factors predicting diabetes progression, and the move to consider additional obesity metrics...

In this episode of Medical News Update, we explore recent updates in the world of diabetes. Stay informed, stay healthy! 00:00 Introduction 00:04 Stem Cell Therapy Breakthrough 00:20 Impact of Early Dietary Choices 00:33 Diabetes and Brain Health 00:46 Global Diabetes Projections 01:00 Conclusion and Sign Off

In this episode of the Medical News Update, we discuss the FDA's approval of Zepbound (tirzepatide), a groundbreaking drug for treating moderate to severe obstructive sleep apnea in adults with obesity. Learn about the condition, how the medication works, clinical trial results, and potential risks and limitations. Stay informed about the latest medical advancements with our updates. 00:00 Introdu...